Fresenius medical care announces divestment of select laboratory assets to quest diagnostics

Quest to provide comprehensive dialysis-related laboratory and water testing services to fresenius medical care owned and affiliated clinics in the united states bad homburg, germany and secaucus, n.j. , feb. 24, 2025 /prnewswire/ -- fresenius medical care (xetra: fme; nyse: fms), the world's leading provider of products and services for individuals with renal disease, and quest diagnostics (nyse: dgx), a leading provider of diagnostic information services, today announced that, under terms of a definitive acquisition agreement, quest will acquire select assets of fme's wholly owned spectra laboratories, a leading  provider of renal-specific laboratory testing services in the u.s.   in addition, under a separate agreement, quest will provide comprehensive laboratory services related to end-stage kidney disease (eskd) and specialized water testing for patients and providers served by dialysis centers operated by fresenius medical care and its wholly owned and joint-venture partners in the united states.
FMS Ratings Summary
FMS Quant Ranking